Viewing Study NCT00379119



Ignite Creation Date: 2024-05-05 @ 5:04 PM
Last Modification Date: 2024-10-26 @ 9:27 AM
Study NCT ID: NCT00379119
Status: TERMINATED
Last Update Posted: 2012-10-11
First Post: 2006-09-19

Brief Title: Effect of Androgen Blockade Therapy on Thymus Function in Older Patients Who Have Undergone Radical Prostatectomy for Localized Prostate Cancer
Sponsor: University of California San Francisco
Organization: University of California San Francisco

Study Overview

Official Title: Androgen Blockade Therapy and Thymic Function in Individuals Over 50 Years of Age With Adenocarcinoma of the Prostate A Cross-Sectional Study
Status: TERMINATED
Status Verified Date: 2012-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: low accrual
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: RATIONALE Studying changes in thymus function in patients who have been undergoing androgen blockade therapy for prostate cancer may help doctors learn more about how well patients will respond to treatment may help in planning cancer treatment and may help the study of cancer in the future

PURPOSE This clinical trial is studying the effect of androgen blockade therapy on thymus function in older patients who have undergone radical prostatectomy for localized prostate cancer
Detailed Description: OBJECTIVES

Determine if inhibition of sex steroid action is associated with increased thymic size in older patients who have undergone radical prostatectomy for localized adenocarcinoma of the prostate
Determine if inhibition of sex steroid action is associated with an increase in the absolute number or percentage of circulating naive phenotype T cells andor an increase in the frequency of T-cell receptor excision circles in peripheral blood cells

OUTLINE This is a nonrandomized single-blind cohort study Patients are stratified according to hormonal therapy after surgery yes vs no

Patients undergo CT scan of the thymus Blood samples are analyzed by flow cytometry to determine phenotype of T cells

PROJECTED ACCRUAL A total of 40 patients will be accrued for this study

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
UCSF-035511 None None None